NovoCure Ltd cotiza a 14.72 USD y tiene una capitalización bursátil de $1.7B. En los últimos 12 meses ha facturado $699M con un margen de flujo de caja libre del -11.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.13 | $-0.62 | $-0.22 |
| Estimado | $-0.23 | $-0.33 | $-0.51 | $-0.41 |
| Sorpresa | — | +60.6% | -21.6% | +46.3% |
| Métrica | NVCR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 74.5% | 57.0% | +17.5% |
| Operating Margin | -23.5% | -38.6% | +15.1% |
| Net Margin | -20.8% | -33.6% | +12.8% |
| FCF Margin | -11.6% | -13.9% | +2.3% |
| ROE | -40.0% | -40.4% | +0.4% |
| ROA | -16.9% | -32.0% | +15.1% |
| Current Ratio | 2.90 | 2.84 | +0.06 |
| Debt / Equity | 0.57 | 0.28 | +0.29 |